ArticleCancer cell2020
Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 103 citations in OpenAlex.
- Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis.Cancer letters · 2026Article
- Characterizing neurofibromin 1-altered breast cancer through genomic, functional, and clinical analyses.Virchows Archiv : an international journal of pathology · 2026Article
- Early-stage HER2-positive breast cancer in neurofibromatosis type 1: a case report with literature review.Frontiers in oncology · 2026Article
- Subtype distribution, clinical presentation, and molecular spectrum of neurofibromatosis type 1-associated breast cancer.Breast (Edinburgh, Scotland) · 2025Article
- CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them?International journal of molecular sciences · 2025Review
- Rat somatic genome editing enables ER+ breast cancer modeling.bioRxiv : the preprint server for biology · 2025Article
- NF1-depleted ERScience translational medicine · 2025Article
- Breast cancer: pathogenesis and treatments.Signal transduction and targeted therapy · 2025Review
- Pregnancy and the Risk for Cancer in Neurofibromatosis 1.Genes, chromosomes & cancer · 2025Article
- ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Combined therapy with the estrogen receptor ERα and IFNα-2b suppresses HBV replication by inducing GBP1 expression.Frontiers in immunology · 2025Article
- Automatic construction of Petri net models for computational simulations of molecular interaction network.NPJ systems biology and applications · 2024Article
- Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription.EMBO reports · 2024Article
- Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer.Journal of clinical medicine · 2024Review
- NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.Molecular metabolism · 2024Article
- Next-Generation Sequencing in Breast Cancer Patients: Real-World Data for Precision Medicine.Cancer research and treatment · 2024Article
- Article
- ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.Molecular oncology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 4 institutions in 2 countries.
Ze-Yi ZhengLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Meenakshi AnuragLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Jonathan T LeiLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Interdepartmental Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, TX, USA.
Jin CaoDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Purba SinghLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Jianheng PengLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Department of Physical Examination, the First Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
Hilda KennedyLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Nhu-Chau NguyenLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Yue ChenAdrienne Helis Malvin Medical Research Foundation, New Orleans, LA, USA.
Philip LavereDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Jing LiLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Xin-Hui DuLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Department of Bone and Soft Tissue, Zhengzhou University Affiliated Henan Cancer Hospital and College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, P. R. China.
Burcu CakarLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Wei SongLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Beom-Jun KimLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Jiejun ShiLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Sinem SekerLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Doug W ChanLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Guo-Qiang ZhaoDepartment of Bone and Soft Tissue, Zhengzhou University Affiliated Henan Cancer Hospital and College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, P. R. China.
Xi ChenDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Kimberly C BanksGuardant Health, Redwood City, CA, USA.
Richard B LanmanGuardant Health, Redwood City, CA, USA.
Maryam Nemati ShafaeeLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Xiang H-F ZhangLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Suhas VasaikarLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Bing ZhangLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Susan G HilsenbeckLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Wei LiLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Charles E FouldsDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA; Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX, USA.
Matthew J EllisLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA; Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Electronic address: mjellis@bcm.edu.
Eric C ChangLester and Sue Smith Breast Center and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. Electronic address: echang1@bcm.edu.
Baylor College of Medicine · USGuardant (United States) · USHenan Cancer Hospital · CNZhengzhou University · CN
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MTissue Analysis & Molecular Imaging CoreP30DK056338 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI Geoffrey A Preidis · 2001 to 2026
$28.3MTranslational Research in Breast Cancer (SPORE)P50CA186784 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Xiang Zhang · 2014 to 2026
$24.5MVirology CoreP30AI036211 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI BUTEL, JANET S · 1994 to 2015
$21.7MTHE RNA HELICASE EIF4A IS A THERAPEUTIC VULNERABILITY IN TRIPLE-NEGATIVE BREAST CANCERU54CA233223 · NCI · BAYLOR COLLEGE OF MEDICINE · PI MITSIADES, NICHOLAS · 2018 to 2022
$7.0MNOVEL BIOMARKERS FOR AROMATASE INHIBITOR THERAPYR01CA095614 · NCI · WASHINGTON UNIVERSITY · PI ELLIS, MATTHEW J, LUO, JINGQIN · 2003 to 2013
$5.6MTraining Program in Translational Biology and Molecular MedicineT32GM088129 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI ROONEY, CLIONA M., VAN DEN VEYVER, IGNATIA B · 2010 to 2019
$3.0MTranslational Breast Cancer Research Training ProgramT32CA203690 · NCI · BAYLOR COLLEGE OF MEDICINE · PI FUQUA, SUZANNE AW, RIMAWI, MOTHAFFAR FAHED · 2018 to 2022
$1.0MA novel N-Ras pathway driving DCIS to basal-like breast cancerR21CA226567 · NCI · BAYLOR COLLEGE OF MEDICINE · PI CHANG, ERIC C · 2018 to 2019
$377kHigh Kynurenine in Agressive Triple Negative African American Breast CancerR21CA185516 · NCI · BAYLOR COLLEGE OF MEDICINE · PI SREEKUMAR, ARUN · 2014 to 2015
$374kMicro-computed tomography system (Micro-CT)S10RR024547 · NCRR · HOSPITAL FOR SPECIAL SURGERY · PI BOSKEY, ADELE L · 2008 to 2008
$290kNCI NIH HHS P30 CA125123NCI NIH HHS P50 CA186784NCI NIH HHS R01 CA095614NCI NIH HHS R21 CA185516NCI NIH HHS R21 CA226567NCI NIH HHS T32 CA203690NCI NIH HHS U54 CA233223NCRR NIH HHS S10 RR024547NIAID NIH HHS P30 AI036211NIDDK NIH HHS P30 DK056338NIGMS NIH HHS T32 GM088129
Abstract
We report that neurofibromin, a tumor suppressor and Ras-GAP (GTPase-activating protein), is also an estrogen receptor-α (ER) transcriptional co-repressor through leucine/isoleucine-rich motifs that are functionally independent of GAP activity. GAP activity, in turn, does not affect ER binding. Consequently, neurofibromin depletion causes estradiol hypersensitivity and tamoxifen agonism, explaining the poor prognosis associated with neurofibromin loss in endocrine therapy-treated ER
Indexed as
Amino Acid MotifsAnimalsBreast NeoplasmsCell NucleusCo-Repressor ProteinsEstrogen AntagonistsEstrogen Receptor alphaFemaleHumansMCF-7 CellsMice, NudeMice, SCIDMutationNeurofibromin 1ras ProteinsSignal TransductionCo-Repressor ProteinsESR1 protein, humanEstrogen AntagonistsEstrogen Receptor alphaNeurofibromin 1NF1 protein, humanras ProteinsTamoxifenbreast cancerco-regulatorDrosophilaendocrine therapyestrogen receptorGTPaseneurofibromatosisNF1RASyeast
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.